



Appendix 1 – Long Form Disclosure
Information for Vermont Prescribers of Prescription Drugs

AGRYLIN®
 (Anagrelide Hydrochloride)

- This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to Ea. product's FDA-approved label and indication for further information.
- The prices listed below are Average Wholesale Prices ("AWP") as established and made available to the public by a third party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about AWP of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class.
- The prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed. For simplicity, only the smallest package sizes available for Ea. product are included.

Product Name	Manufacturer	NDC	Pkg Size	Package	Pill
Marketed Products:					
Agrylin Oral Capsule 0.5 MG	SHIRE US	54092-0063-01	100	\$ 992.28	\$ 9.92
Other Products:					
Anagrelide HCl Oral Capsule 0.5 MG	TORRENT PH	13668-0453-01	100	\$ 1,116.35	\$ 11.16
Anagrelide HCl Oral Capsule 0.5 MG	TEVA USA	00172-5241-60	100	\$ 1,116.35	\$ 11.16
Anagrelide HCl Oral Capsule 1 MG	TORRENT PH	13668-0462-01	100	\$ 2,406.85	\$ 24.07
Anagrelide HCl Oral Capsule 1 MG	TEVA USA	00172-5240-60	100	\$ 2,406.85	\$ 24.07

Therapeutic classes are listed in the 2004 American Hospital Formulary Service Pharmacologic-Therapeutic Classification published by the American Society of Health System Pharmacists (available at <http://www.ashp.org/ahfs>).